Skip to main content

Table 3 Correlation between clinicopathological features and αSMA in 114 patients with PDAC and in 154 patients with BTCs

From: Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line

  

PDAC

P value

BTC

P value

αSMA

αSMA

αSMA

αSMA

positive

negative

positive n = 83

negative n = 71

n = 67

n = 47

Sex

men

37

21

0.26

46

40

0.26

women

30

26

37

31

Age, median (range)

 

68(34–85)

73(56–83)

0.06

70(43–87)

68(43–86)

0.23

T category

pT0–2

20

9

0.19

56

33

a0.008

pT3–4

47

38

27

38

Lymph node metastasis

absent

32

22

0.92

64

39

a0.003

present

35

25

19

32

Distant metastasis

absent

61

45

0.31

81

62

a0.01

present

6

2

2

9

Lymphatic invasion

absent

6

10

0.06

43

17

a0.01

present

61

37

32

32

Vascular invasion

absent

38

29

0.59

66

37

0.06

present

29

18

9

12

Neural invasion

absent

10

8

0.76

43

15

a0.001

present

57

39

28

34

UICC stage

2

59

44

0.31

69

41

a < 0.001

> 2

8

3

 

14

30

Serum CEA level

< 5 ng/ml

38

29

0.72

63

56

0.62

5 ng/ml

27

18

14

10

Serum CA19–9 level

< 37 U/ml

19

18

0.26

52

28

a0.008

37 U/ml

48

29

28

37

Serum SPan-1 level

< 30 U/ml

18

20

0.09

   

30 U/ml

48

27

  1. αSMA alpha-smooth muscle actin, PDAC: pancreatic ductal adenocarcinoma, BTCs bile tract cancers, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, SPan-1 s-pancreas-1 antigen
  2. ap < 0.05